- $1.76bn
- $1.54bn
- $7.40m
U.S. STOCKS ON THE MOVE-Core & Main, Commercial Metals, Equifax
U.S. STOCKS ON THE MOVE-Toll Brothers, American Eagle Outfitters, Twilio
Wrapup 1: Drugmakers kick off industry conference with two cancer deals
U.S. STOCKS ON THE MOVE-Moderna, Coinbase, Ambrx Biopharma
Ambrx Biopharma surges on J&J's buyout announcement
J&J to buy cancer therapy developer Ambrx for $2 bln (updated)
Johnson & Johnson to buy Ambrx Biopharma for $2 bln
Deals of the day-Mergers and acquisitions
Biotech index narrowly avoids longest annual losing streak
Brief: Ambrx Provides Update On Apex-01, An On-Going Phase 1 / 2 Dose Escalation Study Evaluating Arx517, A Proprietary Psma-Targeting Adc, In Metastatic Castration-Resistant Prostate Cancer
U.S. STOCKS ON THE MOVE-TransUnion, Boeing, Editas
Brief: Ambrx Announces Arx517, A PSMA-Targeted Adc, Demonstrates A Promising 52% Psa50
Brief: Ambrx Biopharma, Inc Files For Mixed Shelf Of Up To $300 Million – SEC Filing
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
U.S. STOCKS ON THE MOVE-Moderna, Aldeyra Therapeutics, Colgate-Palmolive
Brief: Ambrx Provides Safety And Efficacy Data From Ongoing Phase 1/2 APEX-01 Trial Of ARX517 in mCRPC At ESMO Congress
U.S. STOCKS ON THE MOVE-Bluebird bio, Panbela, Northern Trust
U.S. STOCKS ON THE MOVE-Constellation Brands, Baker Hughes, Hasbro
Ambrx Biopharma rises on FDA's 'fast-track' tag for prostate cancer drug